Evoq Remedies Limited (BOM:543500)

Evoq Remedies Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	17.67	0.88	4.52	16.19	10.91	7.15
Depreciation & Amortization	0.71	0.49	0.07	0.04	-	-
Other Operating Activities	-	-	-	-0	0	-0
Change in Accounts Receivable	-26.18	-68.74	154.73	81.82	-185.61	-21.18
Change in Inventory	-4.25	9.06	-10.93	-12.48	-6.34	-0.9
Change in Accounts Payable	-1.28	2.13	38.2	-17.45	-67.83	11.59
Change in Other Net Operating Assets	44.37	-90.05	-133.4	-111.58	-27.51	3.65
Operating Cash Flow	31.04	-146.23	53.2	-43.46	-276.38	0.31
Capital Expenditures	-2.58	-2.58	-0.12	-0.13	-	-
Investing Cash Flow	-2.58	-2.58	-0.12	-0.13	-	-
Short-Term Debt Issued	-	-	-	14.18	81.58	-
Total Debt Issued	-	-	-	14.18	81.58	-
Short-Term Debt Repaid	-	-42.38	-53.38	-	-	-
Total Debt Repaid	-27.97	-42.38	-53.38	-	-	-
Net Debt Issued (Repaid)	-27.97	-42.38	-53.38	14.18	81.58	-
Issuance of Common Stock	-	192.1	-	-	213.32	-
Financing Cash Flow	-27.97	149.72	-53.38	14.18	294.9	-
Net Cash Flow	0.49	0.91	-0.3	-29.41	18.52	0.31
Free Cash Flow	28.46	-148.81	53.08	-43.59	-276.38	0.31
Free Cash Flow Margin	6.99%	-105.01%	84.13%	-16.50%	-164.68%	0.31%
Free Cash Flow Per Share	1.09	-5.98	3.90	-3.21	-27.61	0.31
Cash Interest Paid	-	-	-	0.01	0.05	0
Cash Income Tax Paid	0.65	0.4	1.59	6.65	3.67	-
Levered Free Cash Flow	22.23	-148.89	52.38	-45.49	-266.05	-0.88
Unlevered Free Cash Flow	22.23	-148.89	52.38	-45.49	-266.05	-0.88
Change in Working Capital	12.66	-147.6	48.6	-59.69	-287.29	-6.84

Source: S&P Global Market Intelligence. Standard template. Financial Sources.